Birch Hill Investment Advisors LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 214,269 shares of the company’s stock after acquiring an additional 286 shares during the quarter. Johnson & Johnson comprises 2.4% of Birch Hill Investment Advisors LLC’s portfolio, making the stock its 17th biggest holding. Birch Hill Investment Advisors LLC’s holdings in Johnson & Johnson were worth $37,851,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Lincoln Capital Corp grew its holdings in Johnson & Johnson by 15.9% in the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after buying an additional 183 shares in the last quarter. Ieq Capital LLC grew its holdings in Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after buying an additional 6,154 shares in the last quarter. RFG Advisory LLC grew its holdings in Johnson & Johnson by 2.7% in the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after buying an additional 594 shares in the last quarter. Willis Investment Counsel grew its holdings in Johnson & Johnson by 0.4% in the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after buying an additional 1,358 shares in the last quarter. Finally, FDx Advisors Inc. grew its holdings in Johnson & Johnson by 0.3% in the 3rd quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after buying an additional 153 shares in the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
JNJ has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 1st. StockNews.com initiated coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. UBS Group initiated coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price for the company. Atlantic Securities cut their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Guggenheim began coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price for the company. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $173.00.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter in the prior year, the firm earned $2.67 EPS. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. The ex-dividend date of this dividend is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is presently 94.56%.
Insider Activity
In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
